FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia B

 
Novo Nordisk recently announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN^® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. Novo Nordisk expects to launch REBINYN^® in the U.S. in the first half of 2018.
For more info on REBINYN, read the full press release here.